Literature DB >> 9570540

CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I kappa B alpha and I kappa B beta and sustained activation of nuclear factor-kappa B/c-Rel.

A K Yi1, A M Krieg.   

Abstract

Unmethylated CpG dinucleotides in particular base contexts in oligonucleotides (CpG DNA) rescue WEHI-231 cells from anti-IgM-induced cell cycle arrest and apoptosis. Anti-IgM rapidly elevated the levels of NFkappaB p50/c-Rel heterodimers followed by a decline of p50/c-Rel heterodimers by 3 h and a concomitant increase of p50/p50 homodimers. In contrast, CpG DNA induced and maintained the levels of p50/c-Rel heterodimers in the presence or absence of anti-IgM, while control non-CpG DNA failed to induce NFkappaB activation. Anti-IgM induced IkappaB alpha degradation followed by increased IkappaB alpha protein levels. The levels of IkappaB beta were increased after anti-IgM treatment. In contrast, CpG DNA, but not non-CpG DNA, induced sustained IkappaB alpha and IkappaB beta degradation in the presence or absence of anti-IgM. Inhibition of IkappaB degradation blocked CpG DNA-induced NFkappaB activation and expression of c-myc. Prevention of NFkappaB activation by inhibiting IkappaB degradation also suppressed the ability of CpG DNA to rescue WEHI-231 cells from anti-IgM-induced apoptosis. These results indicate that CpG DNA-mediated sustained activation of NFkappaB depends on the degradation of IkappaB alpha and IkappaB beta and is required for the CpG DNA-mediated anti-apoptosis gene expression and the protection against anti-IgM-induced apoptosis of WEHI-231 cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9570540

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  The response of human B lymphocytes to oligodeoxynucleotides.

Authors:  H Liang; P E Lipsky
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Signal transduction induced by immunostimulatory CpG DNA.

Authors:  A M Krieg
Journal:  Springer Semin Immunopathol       Date:  2000

Review 3.  Rescue of B cells from apoptosis by immune stimulatory CpG DNA.

Authors:  A M Krieg; A K Yi
Journal:  Springer Semin Immunopathol       Date:  2000

Review 4.  Mechanisms of immune stimulation by bacterial DNA.

Authors:  D S Pisetsky
Journal:  Springer Semin Immunopathol       Date:  2000

Review 5.  Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons.

Authors:  S Sun; X Zhang; D Tough; J Sprent
Journal:  Springer Semin Immunopathol       Date:  2000

6.  Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs.

Authors:  A M Krieg; T Wu; R Weeratna; S M Efler; L Love-Homan; L Yang; A K Yi; D Short; H L Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

7.  The role of the macrophage scavenger receptor in immune stimulation by bacterial DNA and synthetic oligonucleotides.

Authors:  F G Zhu; C F Reich; D S Pisetsky
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

8.  CpG-ODN-mediated TLR9 innate immune signalling and calcium dyshomeostasis converge on the NFκB inhibitory protein IκBβ to drive IL1α and IL1β expression.

Authors:  Robyn De Dios; Leanna Nguyen; Sankar Ghosh; Sarah McKenna; Clyde J Wright
Journal:  Immunology       Date:  2020-03-18       Impact factor: 7.397

9.  The arthritogenic and immunostimulatory properties of phosphorothioate oligodeoxynucleotides rely on synergy between the activities of the nuclease-resistant backbone and CpG motifs.

Authors:  Jan L Bjersing; Kristina Eriksson; Andrej Tarkowski; L Vincent Collins
Journal:  Inflammation       Date:  2004-02       Impact factor: 4.092

10.  Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.

Authors:  Jiyuan Ke; R Lakshman Chelvarajan; Vishal Sindhava; Darrell A Robertson; Lazaros Lekakis; C Darrell Jennings; Subbarao Bondada
Journal:  Mol Cancer       Date:  2009-12-31       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.